{"id":"NCT00855959","sponsor":"AstraZeneca","briefTitle":"Study to Evaluate Efficacy and Safety of Pulmicort Respules in Japanese Adult Asthmatic Patients","officialTitle":"An Evaluation of Efficacy and Safety of Corresponding Doses of Pulmicort Turbuhaler® and Pulmicort Respules® in Japanese Asthmatic Adult Patients (Open, Multicenter, Phase III Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-02","primaryCompletion":"2009-08","completion":"2009-08","firstPosted":"2009-03-05","resultsPosted":"2011-03-11","lastUpdate":"2011-03-11"},"enrollment":108,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Budesonide","otherNames":["Pulmicort"]},{"type":"DRUG","name":"Pulmicort Turbuhaler","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to show similarity of efficacy on Pulmicort Respules 1.0 mg/day or 2.0 mg/day for 6 weeks in the treatment period and the corresponding doses of Pulmicort Turbuhaler 400 μg/day or 800 μg/day for 4 weeks in the observation period in Japanese adult asthmatic patients with age of 16 years or older.","primaryOutcome":{"measure":"Morning Peak Expiratory Flow (mPEF)","timeFrame":"6 weeks","effectByArm":[{"arm":"Pulmicort Turbuhaler and Pulmicort Respules","deltaMin":3.3,"sd":21.4}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":4},"locations":{"siteCount":6,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":108},"commonTop":["Nasopharyngitis"]}}